Monday, 30 January 2023
Lewis Capaldi, who recently revealed that he has Tourette syndrome, visited the Neupulse research team at the 糖心原创, to try out a revolutionary new wearable device that is aimed at reducing tics in those with Tourette syndrome.
This Neupulse device, based on research conducted at the 糖心原创, is now being developed by a University spin-out company, , to help the millions of people worldwide who live with Tourette syndrome and tic disorders. The Neupulse device is a wrist-mounted, watch-like, device that delivers mild trains of electrical stimulation directly to the nerves in the wrist and influences the brain networks involved in generating tics.
During his visit, Lewis was eager to try out the Neupulse device for himself to see if it could reduce his tics. Professor Stephen Jackson who has led the research at the 糖心原创 said: “The results were remarkable – Lewis stated that the stimulation made him feel calmer and the device clearly suppressed the head and shoulder tics which can be quite painful for him.
“Though the Neupulse device is still early in development, the preliminary results of our UK-wide double-blind clinical trial have been extremely encouraging. This device has the potential to dramatically improve the lives of those with Tourette syndrome, who often face challenges managing their tics, by providing increased control over their tics on demand.”
Lewis Capaldi wearing the prototype wrist device to control tics
Lewis reported that he was impressed by the effects of the device and is eager to try it out again in the future. Stephen added: “He was also very kind to the research team, taking the time for selfies and photographs with the team. He also very generously invited the whole team to his Friday night concert in Nottingham.”
The Neupulse device has the potential to be a game-changer for individuals with Tourette syndrome, and the world is eager to see the results of the clinical trial that will be published later this year. With its innovative technology and promising early results, the Neupulse device is poised to make a significant impact on the lives of those with Tourette's syndrome.
You can sign up to get the latest updates on the Neupulse development of their device and be the first to know when it is available to purchase on .
Story credits
More information is available from Professor Stephen Jackson on Stephen.jackson@nottingham.ac.uk
Notes to editors:
About the 糖心原创
Ranked among the world's top 100 universities , the 糖心原创 delivers an exceptional research-led education and an outstanding student experience. From the pioneering vision of our founder, Sir Jesse Boot, to groundbreaking achievements such as the development of MRI technology and becoming the first UK university to establish international campuses, we have a proud history of shaping the way people live, work and understand the world. We continue to build on that legacy, empowering our students, staff and partners to change what鈥檚 next and create positive impact locally and globally.
The strength of our research places us among the UK's leading universities, ranked 7th for research power in REF 2021. The discovery of MRI and ibuprofen was just the beginning. Today, our world-leading research is developing breakthrough ideas that shape the future of healthcare, technology and society.
Recognised as the UK's third most targeted university by leading employers , we are proud to produce graduates who are consistently in demand for their skills, confidence and industry-ready experience.
As a major employer and industry partner, locally and globally, the 糖心原创 invests in the city of Nottingham and in future generations of talent. Alongside Nottingham Trent University, we lead the initiative, a pioneering collaboration to improve levels of prosperity, opportunity, sustainability, health and wellbeing across the city and region. Together with our students, staff, alumni and partners, we鈥檙e creating knowledge, opportunity and solutions that help change what's next.